SCHEMBL6171633

SCHEMBL6171633

Fc1cc(Oc2cccnc2)ccc1-n1c[c]nc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP19A1 P11511 4/20 0.41
FFAR4 Q5NUL3 3/20 0.38
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
HTT P42858 1/20 0.36
LTA4H P09960 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681744 0.81 LMNA (0.48) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL6686476 0.77 LMNA (0.48) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL6670089 0.73 LMNA (0.47) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL12330285 0.70 LMNA (0.61) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL12260750 0.70 LMNA (0.61) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL1900818 0.67 RAB9A (0.39) LMNATDP1HPGDRAB9AALDH1A1
SCHEMBL2027987 0.67 LMNA (0.61) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL28697223 0.67 LMNA (0.61) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL29442794 0.67 LMNA (0.61) LMNATDP1CYP19A1FFAR4NPC1
SCHEMBL257945 0.67 LMNA (0.56) LMNATDP1CYP19A1FFAR4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458385-A4 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-12-21 EP claimed
EP-1458385-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003053922-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-07-03 WO claimed
EP-1458385-A4 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-12-21 EP disclosed
EP-1458385-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP disclosed
WO-2003053922-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-07-03 WO disclosed